Vertex deal cashes out Crinetics (NASDAQ: CRNX) director’s stock and options
Crinetics Pharmaceuticals (CRNX) director Vivaldi Coelho Rogerio reported disposing of stock and options on September 1, 2026, following the company's merger with Vertex Pharmaceuticals. Each Crinetics share was converted into $85.00 in cash. The director's dispositions included common stock, restricted stock units, and stock options, all converted according to the merger terms.
How this was made
The 30-second read
Why it matters
The disclosed insider transactions confirm the merger terms and provide transparency on cash proceeds, but do not introduce new market-moving information beyond the merger completion.
Market read
The filing confirms the merger cash consideration and insider cash-out, offering limited actionable insight for traders.
What to watch
Potential tax implications for the director and any post-merger integration risks for Vertex are not addressed.
Background
Crinetics Pharmaceuticals merged into a wholly owned subsidiary of Vertex Pharmaceuticals, with each share converted to $85 cash. The Form 4 filing details the director's dispositions.
Ticker impact
Director Vivaldi Coelho Rogerio disclosed cash dispositions of stock, RSUs and options following the merger of Crinetics into Vertex at $85 per share.
Limited short-term impact; price may stabilize around the merger cash consideration.
Form 4 filing is a primary source; the disclosed cash amount and transaction size are clear and directly tied to the merger.
Market effects
Confirms completion of Vertex's acquisition of Crinetics, potentially consolidating the biotech M&A landscape.
Minimal; primarily affects US biotech investors.
Low; limited to shareholders of CRNX and related biotech sector participants.
Counterpoint
The insider cash-out could signal confidence in the merger terms, suggesting the $85 per share is fair value.
Key entities
- CompanyCrinetics Pharmaceuticals, Inc.
Target of the merger, now a subsidiary of Vertex.
- CompanyVertex Pharmaceuticals Incorporated
Acquirer in the merger.
- IndividualVivaldi Coelho Rogerio
Director of Crinetics who reported the dispositions.
